Abstract
The article published by McMahon and colleagues [1] reports the first clinical trial in humans using a monoclonal neutralizing antibody (mAb) attached to a detection system with radioisotopes and measured by positron-emission tomography (PET) to assess the neutralizing effect of the mAb among the potential reservoirs of human immunodeficiency virus (HIV) in volunteers with and without HIV infection. The series of experiments implemented by the team shows the effort invested to obtain all measurements with the highest accuracy and precision crucial for this sort of studies.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
